Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice

Article Category: Research Article

Published Online: May 04, 2021

Page range: 491 - 498

Received: Sep 27, 2021

Accepted: Mar 07, 2021

DOI: https://doi.org/10.2478/raon-2021-0021

Keywords

PD-L1 inhibitor, urothelial cancer, bladder, atezolizumab, overall survival, immune checkpoint inhibitor, prognostic factors

© 2021 Marina Mencinger, Dusan Mangaroski, Urska Bokal, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.